

PRODUCT MONOGRAPH

phl-TRYPTOPHAN

(L-Tryptophan)

500 mg & 1 g Tablets

500mg Capsules

Adjunct in the Management of Affective Disorders

Pharmel Inc.
8699, 8th Avenue
Montreal, Quebec, Canada
H1Z 2X4

Date of Preparation:
December 9, 2004

Control Number: 095684, 095685

phl-TRYPTOPHAN
(L-Tryptophan)
500 mg & 1g Tablets
500 mg Capsules

THERAPEUTIC CLASSIFICATION

Adjunct in the Management of Affective Disorders

ACTION AND CLINICAL PHARMACOLOGY

The rationale for the use of L-tryptophan in affective disorders is based on clinical findings of more than 20 years ago, that L-tryptophan increases 5-HT (serotonin) synthesis in the central nervous system of humans. It has been demonstrated in clinical trials that oral ingestion of L-tryptophan in humans caused a significant increase in the level of the serotonin metabolite, 5-hydroxyindoleacetic acid (5-HIAA), in the lumbar cerebrospinal fluid, indicating an increased turnover of serotonin in the CNS.

L-tryptophan is one of the eight essential amino acids. The minimum daily requirements are said to be 0.25 g for males and 0.15 g for females. It is present in the hydrolysates of most proteins, the average western diet containing between 1 and 3 grams per day. There are two major metabolic pathways for L-tryptophan, the first to serotonin, the second to nicotinic acid. Approximately 98% of dietary L-tryptophan is metabolized into nicotinic acid and only a very small amount is being metabolized to serotonin via the intermediary stage of 5-hydroxy-tryptophan (5-HTP). Tryptophan hydroxylase, the enzyme responsible for this step, is the rate-limiting enzyme for serotonin production and is normally only about half-saturated. Central nervous system serotonin is metabolized by monoamine oxidase to 5-HIAA.

A comparative bioavailability study was performed using phl-TRYPTOPHAN 1 g tablets (Pharmel Inc.) *versus* TRYPTAN 1 g tablets (ICN Canada Ltd.) in 16 healthy male volunteers. A single 1 g oral dose was administered. The results are summarized in the following table:

SUMMARY OF COMPARATIVE BIOAVAILABILITY DATA

[after oral administration (1 x 1 g tablet) in the fasting state]

phl-TRYPTOPHAN 1 g Tablets (Pharmel Inc., Canada -- Lot #591022)

versus

TRYPTAN 1g Tablets (ICN Canada Ltd.) -- Lot #OC5428

Parameter	Geometric Mean Arithmetic Mean (CV %)		Ratio of Geometric Means (90% Conf. Limit)
	Test	Reference	
AUC _T (µg·h/mL)	294.44 297.02 (13.6)	299.18 303.79 (17.9)	98.4
C _{max} (µg/mL)	47.51 48.21 (17.6)	49.50 50.40 (19.1)	96.0
T _{max} (hr)	1.19 (0.44)	1.44 (0.31)	--
T _{1/2_{el}} (hr)	4.72 (2.21)	4.78 (2.39)	--

T_{max} and T_{1/2_{el}} -- arithmetic mean with standard deviation in parenthesis.

A comparative bioavailability study was performed using phl-TRYPTOPHAN 500 mg capsules (Pharmel Inc.) *versus* TRYPTAN 500 mg capsules (ICN Canada Ltd.) in 36 healthy male volunteers. A single 500 mg oral dose was administered. The results are summarized in the following table:

SUMMARY OF COMPARATIVE BIOAVAILABILITY DATA

[after oral administration (1 x 500mg capsule) in the fasting state]

phl-TRYPTOPHAN 500 mg Capsules (Pharmel Inc., Canada -- Lot #671202)

versus

TRYPTAN 500mg Capsules (ICN Canada Ltd.) -- Lot #7K2892

Parameter	Geometric Mean Arithmetic Mean (CV %)		Ratio of Geometric Means
	Test	Reference	
AUC _T (µg·h/mL)	36.77 40.23 (41.5)	37.92 42.46 (55.4)	97
AUC _∞ (µg·h/mL)	41.21 44.57 (40.8)	39.91 46.06 (66.0)	103
C _{max} (µg/mL)	17.34 18.78 (36.4)	18.26 19.01 (27.0)	95
T _{max} (hr)	1.00 (57.5)	1.00 (41.7)	---
T _{1/2el} (hr)	1.17 (74.7)	1.20 (96.8)	---

T_{max} and T_{1/2el} -- arithmetic mean with standard deviation in parenthesis.

INDICATIONS AND CLINICAL USE

L-tryptophan is used as a valuable adjunct to antidepressant drug treatment in the management of patients suffering from depressive disorders (bipolar affective disorders). An adjunctive effect has been observed in some cases when L-tryptophan is given in combination with lithium in bipolar patients with mania or depression for whom lithium alone or in combination with neuroleptics or tricyclics has been shown to have little or no effect. Clinical observations suggest the possibility that the combination of lithium and L-tryptophan may reduce the need for the higher, more toxic, doses of lithium necessary to control acute mania.

CONTRAINDICATIONS

L-tryptophan is contraindicated in patients with known sensitivity to L-tryptophan or any other compound in the formulation.

WARNINGS

L-tryptophan should not be given to patients suffering from the following conditions or should be prescribed only under close supervision.

Bladder Cancer

To minimize the risk of bladder cancer, it may be recommended to give vitamin B6 supplements if the L-tryptophan doses are many times in excess of those consumed normally in dietary protein. An increased incidence rate of bladder cancer has been observed in experimental animals after implantation of pellets containing any of the seven tryptophan metabolites formed by tryptophan pyrrolase. Active metabolites included kynurenine, 3-hydroxykynurenine, 3-hydroxyanthranilic acid, and xanthurenic acid, but not tryptophan itself. Vitamin B6 has been reported to correct the metabolism of L-tryptophan and to reduce the metabolites to normal levels. A large study carried out by the National Cancer Institute did not find L-tryptophan to produce cancer in either rats or mice. Elevated levels of L-tryptophan metabolites in the urine have been reported both in bladder cancer patients relative to controls, and in patients who had a recurrence of cancer relative to those who did not, and in patients taking oral contraceptives or hormones.

Diabetes Mellitus

Xanthurenic acid, which is increased on L-tryptophan loading, has a diabetogenic action in animals, possibly due to its ability to bind insulin, suggesting caution in the use of tryptophan in patients with a family history of diabetes.

Achlorhydria / Malabsorption

In ruminants, oral L-tryptophan caused pulmonary edema and emphysema, mediated by bacterial conversion of L-tryptophan to skatole (3-methylindole). This is not normally of concern in humans except where bacteria exist in the gastrointestinal tract due to conditions such as achlorhydria, or where L-tryptophan reaches the bacterial populations lower in the gastrointestinal tract due to malabsorption.

Cataract Formation

Animal data suggest that photooxidation of L-tryptophan and some of its metabolites, such as kynurenine, may be involved in cataract formation. Although there is no evidence that this occurs in humans, L-tryptophan administration is likely to raise lenticular tryptophan and kynurenine concentrations, and this might make subjects more susceptible to cataract formation, particularly if exposed to ultraviolet light.

PRECAUTIONS

Drug interactions between tryptophan and other CNS-affecting drugs have been reported. A higher occurrence of side effects was reported when tryptophan was given in combination with monoamine oxidase inhibitors (MAOI). The most common side effects caused by this drug combination were dizziness, nausea and headache. At a dosage of 20–50 mg/kg tryptophan in addition to MAOI, the following side effects have been reported: ethanol-like intoxication, drowsiness, hyperreflexia and clonus. Single case reports of adverse reactions to the drug combination include hypomanic behaviour, ocular oscillation, ataxia, and myoclonus. Some of these reactions resemble the "serotonin syndrome" seen in experimental animals, which consists of tremor, hypertonus, myoclonus, and hyperreactivity. These symptoms disappear soon after cessation of tryptophan, and no detrimental long-term effects have been reported.

When tryptophan was given in combination with fluoxetine, the following side-effects have been reported, but disappeared as soon as the medication was discontinued. Neither drug alone caused similar side-effects: agitation, restlessness, poor concentration, nausea, diarrhea, and worsening of obsessive-compulsive disorder.

Patients taking high doses of L-tryptophan should not be protein deprived since an amino acid imbalance can ensue.

ADVERSE REACTIONS

L-tryptophan, in doses below 5 g/day may cause dry mouth and drowsiness. In higher doses (9–12 g/day) nausea, anorexia, dizziness and headache have been reported.

Side effects disappear when medication is continued and in most cases only a light dizziness may persist. Sexual disinhibition has been reported in some patients with emotional disorders.

L-tryptophan, when given with lithium, might increase some side effects associated with lithium therapy by potentiating the lithium effect (nausea, vomiting, dermatological eruptions, psoriasis, alopecia).

SYMPTOMS AND TREATMENT OF OVERDOSAGE

According to the toxicity described, symptoms of overdose would include vomiting and might include serotonin syndrome symptoms. Treatment of overdose would be symptomatic with close monitoring and support of vital systems as necessary.

DOSAGE AND ADMINISTRATION

Clinical reports on the use of L-tryptophan as an adjunct in the management of affective disorders have indicated a dose of 8–12 g/day to be the most effective one. Lower doses have been reported to be effective in combination with other antidepressants. Some patients may not tolerate 12 g/day but might still benefit from doses reduced to 8 g/day.

The treatment might be initiated with 12 g per day of phl-TRYPTOPHAN (L-tryptophan), given in 3–4 equally divided doses. Administration with meals or snacks is recommended to reduce the incidence of nausea. The dose and frequency of administration may have to be adjusted to the patient's need and tolerance.

A small number of bipolar patients are particularly sensitive to L-tryptophan and will not tolerate higher doses than 1 or 2 g/day. Patients on concomitant medication should be monitored for possible reduction of the concomitant medication since phl-TRYPTOPHAN may enhance their efficacy.


If phl-TRYPTOPHAN is used in the acute treatment of mania in conjunction with lithium, it will potentiate some of the side effects associated with lithium such as nausea and vomiting. Thus, often it will be necessary to decrease the lithium dosage, especially when it is given in doses above 900–1200 mg/day. In manic-depressive illness chronically treated with lithium, the lithium dose may need to be decreased when phl-TRYPTOPHAN is added because of increased side effects. In these patients, phl-TRYPTOPHAN tends to produce an increase in lithium concentrations; thus it is important to monitor the lithium concentration closely for at least two weeks after the addition of phl-TRYPTOPHAN.

With some of the more sedative neuroleptics and antidepressants, if phl-TRYPTOPHAN is added, an increased incidence of sedation may occur.

PHARMACEUTICAL INFORMATION

Drug Substance

Brand Name: phl-TRYPTOPHAN
Proper Name: L-Tryptophan
Chemical Name: L-2-Amino-3-(indol-3-yl) propionic acid
Structural Formula:



Molecular Formula: C₁₁
H₁₂N₂O₂

Molecular Weight: 204.23 g/mol

Physical form: White to slightly yellowish white crystals or crystalline powder, having a slightly bitter taste.

Solubility: Soluble in water; slightly soluble in alcohol or soluble in hot alcohol; practically insoluble in ether; soluble in dilute hydrochloric acid.

pKa and pH values: The pH of a 1 in 100 solution is between 5.5-7.0.

Partition co-efficient: Log P(octanol water partition coefficient) -1.06.

Melting point: 280-285°C.

Composition

phl-TRYPTOPHAN tablets contain: L-tryptophan and as non-medicinal ingredients: carboxymethylcellulose sodium, croscarmellose sodium, hydroxypropyl methylcellulose, magnesium stearate, polyethylene glycol.

phl-TRYPTOPHAN capsules contain: L-tryptophan and as non-medicinal ingredients: carboxymethylcellulose sodium, croscarmellose sodium, magnesium stearate, gelatin, titanium dioxide.

Stability and Storage Recommendations

Store at room temperature (15-30°C). Keep bottles tightly closed; protect from heat and light.

AVAILABILITY OF DOSAGE FORMS

phl-TRYPTOPHAN 500mg:

Each white, opaque, size # 00 Coni-snap capsule printed “P” logo and “T 500” in black ink on both body and cap, contains 500 mg of L-Tryptophan, USP. Bottles of 100 and 250 capsules.

Each white to off-white, oblong, clear film-coated tablet is imprinted with “P” logo on one side and

“T5” on the other side and contains 500 mg of L-tryptophan, USP.

Bottles of 100, 250 and 500 tablets.

phl-TRYPTOPHAN 1g:

Each white, oblong, clear film-coated tablet is imprinted with “P” logo on one side and “T1” on the other side and contains 1 g of L-tryptophan, USP.

Bottles of 100 and 250 tablets.

INFORMATION TO THE CONSUMER

For better results, phl-TRYPTOPHAN should be taken with a protein-low, carbohydrate-rich snack or meal.

TOXICOLOGY

In animals the toxicity of parenterally administered tryptophan and other amino acids is attributed to ammonia poisoning. In rabbits, it causes histopathological changes in the kidney tubules, and large amounts given in conjunction with a low-protein diet cause death within a few days. It provokes a severe hyperglycemia which in the case of the l-isomer is not sustained since the animals die in a hypoglycemic state. L-tryptophan in toxic doses also causes marked glycosuria and loss of glycogen from skeletal muscle and liver. Some L-tryptophan metabolites cause experimental lymphomas or leukemias. The LD₅₀ for L-tryptophan in the rat is 1.6 g/kg.

Carcinogenicity of L-tryptophan has been reviewed based on early findings relating bladder tumors in rats to aromatic amines and l-tryptophan. Experiments designed to provoke urinary bladder tumors by oral or subcutaneous administration of L-tryptophan or its metabolites, have generally resulted in negative results.

Tests performed on behalf of the National Cancer Institute (Bethesda, Md), using male and female rats and mice given large supplements of L-tryptophan for prolonged periods, did not show a statistically significant occurrence of neoplasm as compared to controls. Under the bio-assay, L-tryptophan was not carcinogenic for the strains of animals used. L-tryptophan and its tested metabolites have not exhibited intrinsic carcinogenic action. L-tryptophan has, however, been reported to promote or inhibit the carcinogenic action of a variety of known carcinogens.

L-tryptophan has been shown to cause hyperglycemia in rat and man, to inhibit gluconeogenesis in rat and man and to promote lipogenesis both in the fasted rat and the fed animal. Patients with scleroderma may exhibit abnormal L-tryptophan metabolism and studies have been carried out in an attempt to reveal a possible relationship between tryptophan and scleroderma. Serotonin given subcutaneously in a high dose for 30 days or more to rats was found to result in a scleroderma-like lesion. It is conceivable that the appearance of a sclerodermatous lesion can be initiated by different factors, among them a high level of kynurenine or metabolites of that amino acid, or of serotonin.

REFERENCES

1. Ayuso Gutierrez JL, Lopez-Ibor Alino JJ. Tryptophan and an MAOI (nialamide) in the treatment of depression: A double-blind study. *Int. Pharmacopsychiatry*, 1971; 6:92-97.
2. Baloh, RW, et al. Myoclonus and ocular oscillations induced by L-tryptophan. *An. Neur* 1982; 11:95-97.
3. Beitman, BD, Dunner DL. L-Tryptophan in the maintenance treatment of bipolar II manic-depressive illness. *Am. J. Psychiatry* 1982; 139:1498-1499.
4. Belongia EA, et al. An investigation of the cause of the eosinophilia - myalgia syndrome associated with tryptophan use. *New England J. Med.* 1990; 232 (6): 357-365.
5. Bowers MB. Cerebrospinal fluid 5-hydroxyindoles and behavior after L-tryptophan and pyridoxine administration to psychiatric patients. *Neuropharmacology* 1970; 9: 599-604.
6. Brewerton TD, Reus VL. Lithium carbonate and L-tryptophan in the treatment of bipolar and schizoaffective disorders. *Am. J. Psychiatry* 1983; 140:757-760.
7. Bryan DJ. The role of urinary tryptophan metabolites in the etiology of bladder cancer. *Am L Clin Nutr* 1971; 24:841-846.
8. Chouinard G, Young SN, Annable L, et al. Tryptophan-nicotinamide, imipramine and their combination in depression. *Acta Psychiat. Scand.* 1979; 59:359-414.
9. Chouinard G, et al. Tryptophan in the treatment of depression and mania. In: van Praag HM, Mendlewicz J, eds. *Advances in Biological Psychiatry*, Vol. 10. Basel: Karger, 1983; 47-66.
10. Cowen PL, Chargin EM. Neuroendocrine response to intravenous Tryptophan in Major depression. *Arch. Gen. Psychiatry* 1987; 44:958-966.
11. Dunning WF, Curtis MR, Maun ME. The effect of added dietary tryptophan on the occurrence of 2-acetylaminofluorene induced liver and bladder cancer in rats. *Cancer Res* 1950; 10:454-459.
12. Fernstrom J, Dard Failer DV. Neutral amino acid in the brain: change in response to food ingestion: *J. Neurochem* 1978; 30:1513-38.
13. Graham-Smith DG. Studies in vivo on the relationship between tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibition and L-Tryptophan. *J. Neurochem* 1971; 18:1053-1066.
14. Gullino P, Winitz M, Birnbaum SM, et al. Studies on the metabolism of amino acids and

- related compounds in vivo: Toxicity of essential amino acids, individually and in mixtures, and the protective effect of l-arginine. *Archs Biochem Biophys* 1956;64:319-332.
15. Hery F, Simonner G, Bourgoïn S, et al. Effect of nerve activity on the in vivo release of (3h) serotonin continuously formed from L-(3H)tryptophan in the caudat nucieus of the cat. *Brain Res* 1970; 169:317-334.
 16. Hyypa MT, Joima T, Riekkinen P, et al. Effects of L-tryptophan treatment on central indoleamine metabolism and short-lasting neurological disturbances in multiple sclerosis. *J Neural Transm* 1975; 37:297-304.
 17. Jorgensen AJF, Majumdar APN. Force-feeding on amino acid incorporation into ferritin, transferrin, and mixed proteins of liver, brain and kidneys in vivo. *Biochem.Med* 1976; 16:37-46.
 18. Meier AH, Wilson, JM. Tryptophan feeding adversely influences pregnancy, *Life Sci* 1983; 32:1193-1196.
 19. Modigh K. Central and peripheral effects of 5-Hydroxytryptophan on Motor activity in mice. *Psychopharmacology* 1972; 23:48-54.
 20. Modigh K. Effects of L-tryptophan on motor activity in mice. *Psychopharmacology* 1973; 30:123-143.
 21. Murphy DL, Baker M, Goodwin FK, et al. L-Tryptophan in affective disorders: Indoleamine changes and differential clinical effects. *Psychopharmacology* 1974; 34:11-20.
 22. Puizilout JJ, Gaudin-Chazal G, Daszuta A, et al. Release of endogenous serotonin from "encephale isole" cats. II. Correlations with raphe neuronal activity and sleep and wakefulness. *J. Physiol* 1979; 75:531-537.
 23. Radomski JL, Glass EM, Deichmann WB Transitional Cell Hyperplasia in the bladders of dogs fed dl-tryptophan. *Cancer Res* 1971; 31:690-1694.
 24. Smith B, Prockop DJ. Central-nervous-system effects of ingestion of L-tryptophan by normal subjects. *N. Engl. J. Med* 1962; 267:1338-1341.
 25. Ternaux JP, Boireau A, Bourgoïn S. In vivo release of 5-HT in the lateral ventricle of the rat: Effects of 5-Hydroxytryptophan and tryptophan. *Brain Res* 1976; 101: 533-548.
 26. Yuwiler A, Brammer GL, Morley JE, et al. Short-term and repetitive administration of oral tryptophan in normal men. *Arch Gen Psychiatry* 1981; 38:619-626.